arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Organogenesis Holdings Inc.

ORGO
$1.85 ▼ -0.15 (-7.50%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
42 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
50
Health
Fair
Neutral
auto_awesome

Analytical Summary

Organogenesis Holdings Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $236.4M
Dividend Yield
Revenue Growth -57.1%
Op. Margin -185.1%
ROIC -21.9%
FCF / Share $0.14
Trailing P/E
Price / Book 1.0x
FCF Yield 7.6%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

42-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$37.23M
↓ -57.1%
Net Income Profit after all expenses
$-53.16M
↓ -182.1%
Operating Margin Operating profit as % of sales
-185.1%
↓ -759.7% 51th
FCF / Share Free cash flow per share
$0.14
↑ +2015.2%
Long-Term Debt Long-term obligations
$62.34M
↓ -2.2%

Health Breakdown

Profitability
41
Returns
75
Cash Quality
12

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 11 years · 42 quarters